Research spotlight: Factors contributing to treatment resistance in CAR T therapies for solid tumors
Russell W. Jenkins, MD, PhD, a physician investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of Medicine at Harvard Medical School ...
Healio15d
Biotech firm to advance novel CAR T-cell therapy for rare, fatal pediatric brain tumor
A clinical-stage biotechnology company will advance a novel autologous chimeric antigen receptor T-cell therapy that targets the immune checkpoint B7-H3 for diffuse intrinsic pontine glioma, or DIPG, ...
Targeted Oncology16d
FDA Grants B7-H3–Targeted ADC Breakthrough Status in Osteosarcoma
The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of ...
Nature4y
Propelling Korea’s oncology science globally
Preclinical tests show that the ADC binds to B7-H3 on cancer cells with high affinity ... that target prostate-specific membrane antigen (PSMA). Anti-PSMA radiopharmaceuticals typically use ...